Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Pharmaceutical Research|February 12, 2002
Modeling the pharmacokinetics and pharmacodynamics of a unique oral hypoglycemic agent using neural networksSam H Haidar, Steven B Johnson, Michael J Fossler, et al.
The AAPS Journal|August 30, 2008
Evaluation of a scaling approach for the bioequivalence of highly variable drugsSam H Haidar, Fairouz Makhlouf, Donald J Schuirmann, et al.
The Annals of Pharmacotherapy|September 25, 2009
Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug AdministrationBarbara M Davit, Patrick E Nwakama, Gary J Buehler, et al.
Pharmaceutical Research|September 25, 2007
Bioequivalence approaches for highly variable drugs and drug productsSam H Haidar, Barbara Davit, Mei-Ling Chen, et al.
The AAPS Journal|May 1, 2008
Highly variable drugs: observations from bioequivalence data submitted to the FDA for new generic drug applicationsBarbara M Davit, Dale P Conner, Beth Fabian-Fritsch, et al.
Journal of Pharmaceutical Sciences|September 17, 2015
Effect of Common Excipients on the Oral Drug Absorption of Biopharmaceutics Classification System Class 3 Drugs Cimetidine and AcyclovirSoundarya Vaithianathan, Sam H Haidar, Xinyuan Zhang, et al.
Journal of Pharmaceutical Sciences|March 30, 2016
Reply to "On the Effect of Common Excipients on the Oral Absorption of Class 3 Drugs"Soundarya Vaithianathan, Sam H Haidar, Xinyuan Zhang, et al.
The AAPS Journal|October 12, 2012
Common reasons for "for-cause" inspections in bioequivalence studies submitted to the Food and Drug AdministrationBing V Li, Barbara M Davit, Christina H Lee, et al.
Pageof 2